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Background
Multicentric Castleman Disease (MCD) is an idiopathic
lymphoproliferative disorder, exceptionally reported in
children, probably due to an increase of interleukin 6
secretion. MCD is characterized by systemic lymphade-
nopathy and constitutional inflammatory symptoms
including severe growth retardation. Previous studies in
a d u l ts h o w e dt h a ta n t i - i n t e r l e u k i n6r e c e p t o ra n t i b o d y
alleviated symptoms and biochemical abnormalities of
MCD.
Aim
We describe efficacy and safety of tocilizumab (TCZ) in
two children with MCD. Moreover we describe the
long-term effect and dose adjustments in one of them
with sustained remission after 3 years.
Methods
MCD was suspected clinically then confirmed histologi-
cally in both cases. Tocilizumab was administered intra-
venously at a dose of 8 mg/kg every 2 weeks.
Results
TCZ treatment alleviated fever and restored growth
velocity in both patients. In parallel biochemical
abnormalities, including hypergammaglobulinemia,
increased C-reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR) returned to normal ranges. For the
first patient, the size of abdominal lymph nodes
decreased but the splenomegaly persisted. For the sec-
ond patient, the multiple profound adenopathies per-
sisted and a hepatic node of 7 mm appeared. The side
effects in both cases were mild but sustained thrombo-
cytopenia. Infusions intervals were spaced after 10
months for the first patient who had sustained remission
since 3 years. The second patient is treated every two
weeks since 8 months.
Conclusions
TCZ is effective and safe in children with MCD. The
redundant effect of the drug allows infusion adjustments
on a long term-administration. However our observa-
tions cannot confirm that TCZ may cure this serious
disease.
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